Purchase Order W81K0225PA067
Award Date 10/1/25
Potential Completion Date 9/30/30
Potential Value $367K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Health Agency awarded a $199,584 firm fixed-price purchase order to Cerus Corporation on January 5, 2024, for the procurement of Intercept Platelet Sets (PN INT2140B). The contract, which extends through September 30, 2028, will be performed at Cerus Corporation's facility in Concord, California. This award represents a continuation of the established relationship between the Defense Health Agency and Cerus Corporation for blood safety technologies, with no set-aside designation...
- The Defense Health Agency awarded a firm fixed-price purchase order to Cerus Corporation on July 1, 2024, with a ceiling value of $106,824 for the supply of Intercept Platelet Small Volume Sets. The contract, which runs through September 1, 2027, supports the U.S. Pacific Command Armed Services Blood Bank Center at the U.S. Naval Hospital Okinawa, Japan, and was awarded on a sole-source basis under Federal Acquisition Regulation 13.106-1(b)(1)(i), reflecting Cerus Corporation's unique...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Cerus Corporation, a for-profit manufacturer of the INTERCEPT Blood System, a pathogen reduction technology for platelets and plasma. The $369,384 contract is for the supply of INTERCEPT Platelet Processing Sets, Dual Storage Containers, and maintenance services for INTERCEPT Blood System illuminators to support medical readiness and blood product safety at military healthcare facilities. The contract has...
- The Defense Health Agency (DOD) awarded a $367,504.80 firm fixed price purchase order to Cerus Corporation to provide INTERCEPT Platelet Processing and Service Maintenance for the Walter Reed National Military Center in Bethesda, Maryland from January 13, 2022 through January 31, 2027. Cerus Corporation will supply its INTERCEPT Blood System for platelets, which utilizes ultraviolet light and riboflavin to inactivate pathogens in platelet components during the collection and storage process,...
- This federal contract award is for the supply of INTERCEPT Platelet Small Volume Sets by Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $104,256.00, was awarded by the Defense Health Agency, a defense agency within the Department of Defense. The contract is a Firm Fixed Price Purchase Order with a period of performance through September 3, 2024. Cerus Corporation has a history of providing its...
- This federal contract award, valued at $127,680.00, was issued by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for the provision of INTERCEPT Platelet Processing Sets, which use Cerus' proprietary INTERCEPT Blood System to inactivate pathogens in blood components. The INTERCEPT system employs riboflavin and ultraviolet light to reduce the risk of transfusion-transmitted infections. This contract does...
- This firm-fixed-price purchase order was awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company, for the provision of INTERCEPT Platelet Processing Sets. Valued at $137,664.00, the contract does not have a set-aside designation. Cerus has received over 20 previous prime federal contract awards from agencies including the DoD, VA, and HHS to provide pathogen reduction technologies, equipment, and associated services to support military and veterans' medical...
- The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...
- This federal contract award was issued by the Bureau of Medicine and Surgery, a defense agency, to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The $138,800 firm-fixed-price contract is for the supply of INTERCEPT Illuminator 60 Hz equipment and INTERCEPT Platelet Processing Sets with Dual Storage, as well as related services, to support the agency's blood product safety requirements. Cerus Corporation's proprietary INTERCEPT Blood System uses...
- This is a firm fixed price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that manufactures the INTERCEPT Blood System technology for pathogen reduction in blood components. The contract is for the DROP SHIPMENT OF INTERCEPT DUAL, with a potential value of $66,624.00 and a completion date of January 1, 2024. Cerus Corporation, the prime contractor, is a for-profit manufacturer that has received over 20 federal contract awards from...